Aliaksei Holik
Director for Discovery and Translational Science Consulting
Aliaksei is a biomedical scientist with over 15 years of experience in research, specializing in the use of computational biology and machine learning to unravel disease mechanisms, identify and validate therapeutic targets, and prioritize patient populations most likely to benefit from these therapies. With a strong background in Molecular Biology and Genetics, he has utilized a wide array of omics technologies throughout the entire research lifecycle, from experimental design and data generation to analysis and translating results into actionable insights.
As Director for Discovery and Translational Science Consulting Services, Aliaksei assists clients, ranging from top pharmaceutical companies to stealth-mode biotechs in their drug discovery and translational research efforts. His support encompasses data curation, management, and analytics services applied to pre-clinical and clinical datasets in order to understand disease and drug action mechanisms, prioritize targets and indications, and identify molecular and clinical biomarkers to pinpoint patient populations with the most favourable response and safety profiles.
Aliaksei holds a PhD in Cancer Biology from Cardiff University and a BSc in Molecular Biology from the University of Edinburgh.
Latest news
Clarivate Launches Derwent Patent Monitor to Enable Fast and Accurate Decision-making with AI
New enterprise solution streamlines IP and R&D patent reviews and accelerates freedom to operate, patentability, and infringement related decisions London, U.K. November 24, 2025. Clarivate Plc (NYSE:CLVT), a leading global provider…
Clarivate RiskMark Wins 2025 LegalTech Breakthrough Award For “LegalTech Predictive AI Solution of the Year”
Annual awards program recognizes companies and products driving innovation in the global legal technology industry AI-powered RiskMark delivers near-instant, data-backed insights London, U.K. November 13, 2025. Clarivate Plc (NYSE:CLVT), a…
